Advertisement

Neurochemical Research

, Volume 41, Issue 10, pp 2797–2809 | Cite as

Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure

  • Mikko Gynther
  • Lauri Peura
  • Monika Vernerová
  • Jukka Leppänen
  • Jussi Kärkkäinen
  • Marko Lehtonen
  • Jarkko Rautio
  • Kristiina M. Huttunen
Original Paper

Abstract

Valproic acid (VPA) has been used to treat epileptic seizures for decades, but it may also possess therapeutic potential in other nervous system diseases. However, VPA is extensively bound to plasma proteins, asymmetrically transported across the blood–brain barrier and metabolized to toxic species in the liver, which all contribute to its severe off-target adverse effects and possible drug–drug interactions. In this study, we evaluated seven amino acid prodrugs of VPA that were targeted to utilize l-type amino acid transporter 1 (LAT1), if they could alter the brain uptake mechanism and systemic pharmacokinetics of VPA. All prodrugs had affinity for LAT1 studied as competitive inhibition of [14C]-l-leucine in human breast cancer (MCF-7) cell line. However, since the ester prodrugs were unstable they were not studied further, instead the corresponding amide prodrugs were used to evaluate their systemic pharmacokinetics in rats and the uptake mechanism via LAT1 into the rat brain. All amide prodrugs were bound to a lesser extent to plasma proteins than VPA and this being independent of the prodrug concentration. Amide prodrugs were also delivered into the brain after intravenous bolus injection. One of the prodrug showed greater brain uptake and high selectivity for LAT1 and it was able to release VPA slowly within the brain. Therefore, it was concluded that the VPA brain concentrations can be stabilized as well as the problematic pharmacokinetic profile can be altered by a LAT1-selective prodrug.

Keywords

Brain uptake Pharmacokinetics Prodrug l-Type amino acid transporter 1 (LAT1) Valproic acid 

Abbreviations

BBB

Blood–brain barrier

3D-QSAR

3-Dimensional quantitative structure–activity relationship

GABA

γ-Amino butyric acid

GC–MS

Gas-chromatography–mass spectrometry

HPLC

High-performance liquid chromatography

LAT1

l-type amino acid transporter 1

MCF-7

Human breast cancer cell line

MCT1

Monocarboxylic acid transporter 1

S9

Subcellular fraction (centrifuged at 9000×g)

VPA

Valproic acid

Notes

Acknowledgments

The work was financially supported by funding of the Academy of Finland [256837], University of Eastern Finland (Postdoctoral program), Päivikki and Sakari Sohlberg’s Foundation, Emil Aaltonen Foundation and Orion Research Foundation. The authors would like to thank Tiina Koivunen for skillful technical assistant with the syntheses, Helly Rissanen for invaluable technical assistance with in vitro bioconversion studies, M.Sc. Johanna Huttunen for performing the in vitro LAT1 affinity studies and Dr. Veli-Pekka Ranta for helpful discussions regarding the pharmacokinetic data analysis as well as Dr. Ewen MacDonald for reviewing the language of the study.

References

  1. 1.
    Aldenkamp A, Vigevano F, Arzimanoglou A, Covanis A (2006) Role of valproate across the ages. Treatment of epilepsy in children. Acta Neurol Scand Suppl 184:1–13CrossRefPubMedGoogle Scholar
  2. 2.
    Ben-Menachem E, Schmitz B, Tomson T, Vajda F (2006) Role of valproate across the ages. Treatment of epilepsy in adults. Acta Neurol Scand Suppl 184:14–27CrossRefPubMedGoogle Scholar
  3. 3.
    Perucca E, Aldenkamp A, Tallis R, Kramer G (2006) Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta Neurol Scand Suppl 184:28–37CrossRefPubMedGoogle Scholar
  4. 4.
    Bialer M (2012) Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 53(Suppl 7):26–33CrossRefPubMedGoogle Scholar
  5. 5.
    Terbach N, Williams RS (2009) Structure–function studies for the panacea, valproic acid. Biochem Soc Trans 37:1126–1132CrossRefPubMedGoogle Scholar
  6. 6.
    Bolanos JP, Medina JM (1997) Effect of valproate on the metabolism of the central nervous system. Life Sci 60:1933–1942CrossRefPubMedGoogle Scholar
  7. 7.
    Belcastro V, D’Egidio C, Striano P, Verrotti A (2013) Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 107:1–8CrossRefPubMedGoogle Scholar
  8. 8.
    Nanau RM, Neuman MG (2013) Adverse drug reactions induced by valproic acid. Clin Biochem 46:1323–1338CrossRefPubMedGoogle Scholar
  9. 9.
    Silva MF, Aires CC, Luis PB, Ruiter JP, L IJ, Duran M, Wanders RJ, Tavares de Almeida I (2008) Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31:205–216CrossRefPubMedGoogle Scholar
  10. 10.
    Kiang TK, Ho PC, Anari, Tong MR, Abbott V, Chang FS, TK (2006) Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 94:261–271CrossRefPubMedGoogle Scholar
  11. 11.
    Italiano D, Spina E, de Leon J (2014) Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol 10:1457–1489CrossRefPubMedGoogle Scholar
  12. 12.
    Johannessen SI, Landmark CJ (2010) Antiepileptic drug interactions-principles and clinical implications. Curr Neuropharmacol 8:254–267CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Barre J, Chamouard JM, Houin G, Tillement JP (1985) Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 31:60–64PubMedGoogle Scholar
  14. 14.
    Svennebring AM (2015) Investigation of the prerequisites for the optimization of specific plasma protein binding as a strategy for the reduction of first-pass hepatic metabolism. Xenobiotica 45:286–301CrossRefPubMedGoogle Scholar
  15. 15.
    Cornford EM, Diep CP, Pardridge WM (1985) Blood–brain barrier transport of valproic acid. J Neurochem 44:1541–1550CrossRefPubMedGoogle Scholar
  16. 16.
    Tamai I, Takanaga H, Maeda H, Sai Y, Ogihara T, Higashida H, Tsuji A (1995) Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids. Biochem Biophys Res Commun 214:482–489CrossRefPubMedGoogle Scholar
  17. 17.
    Hosoya K, Kondo T, Tomi M, Takanaga H, Ohtsuki S, Terasaki T (2001) MCT1-mediated transport of l-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm Res 18:1669–1676CrossRefPubMedGoogle Scholar
  18. 18.
    Kang YS, Terasaki T, Tsuji A (1990) Acidic drug transport in vivo through the blood–brain barrier. A role of the transport carrier for monocarboxylic acids. J Pharmacobiodyn 13:158–163CrossRefPubMedGoogle Scholar
  19. 19.
    Terasaki T, Kang YS, Ohnishi T, Tsuji A (1991) In-vitro evidence for carrier-mediated uptake of acidic drugs by isolated bovine brain capillaries. J Pharm Pharmacol 43:172–176CrossRefPubMedGoogle Scholar
  20. 20.
    Adkison, KDK, Shen DD (1996) Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. J Pharmacol Exp Ther 276:1189–1200PubMedGoogle Scholar
  21. 21.
    Kakee A, Takanaga H, Hosoya K, Sugiyama Y, Terasaki T (2002) In vivo evidence for brain-to-blood efflux transport of valproic acid across the blood–brain barrier. Microvasc Res 63:233–238CrossRefPubMedGoogle Scholar
  22. 22.
    Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W (2007) Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 320:331–343CrossRefPubMedGoogle Scholar
  23. 23.
    Scism JL, Powers KM, Artru AA, Lewis L, Shen DD (2000) Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. Brain Res 884:77–86CrossRefPubMedGoogle Scholar
  24. 24.
    Peura L, Malmioja K, Laine K, Leppanen J, Gynther M, Isotalo A, Rautio J (2011) Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. Mol Pharm 8:1857–1866CrossRefPubMedGoogle Scholar
  25. 25.
    Boado RJ, Li JY, Nagaya, Zhang M, Pardridge C, WM (1999) Selective expression of the large neutral amino acid transporter at the blood–brain barrier. Proc Natl Acad Sci USA 96:12079–12084CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H (2002) Transport of amino acid-related compounds mediated by l-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 61:729–737CrossRefPubMedGoogle Scholar
  27. 27.
    Beaumont K, Webster R, Gardner I, Dack K (2003) Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 4:461–485CrossRefPubMedGoogle Scholar
  28. 28.
    Hosokawa M (2008) Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13:412–431CrossRefPubMedGoogle Scholar
  29. 29.
    Liederer BM, Borchardt RT (2006) Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 95:1177–1195CrossRefPubMedGoogle Scholar
  30. 30.
    Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, Peterson JA, Perkins EJ, Pu YJ, Reutzel-Edens SM, Remick DM, Starling JJ, Stephenson GA, Vaid RK, Zhang D, McCarthy JR (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 52:6958–6961CrossRefPubMedGoogle Scholar
  31. 31.
    Gong T, Huang Y, Zhang ZR, Li LL (2004) Synthesis and characterization of 9-[P-(N, N-dipropyl sulfamide)] benzoylamino-1,2,3,4–4 H-acridine–a potential prodrug for the CNS delivery of tacrine. J Drug Target 12:177–182CrossRefPubMedGoogle Scholar
  32. 32.
    Gynther M, Jalkanen A, Lehtonen M, Forsberg M, Laine K, Ropponen J, Leppanen J, Knuuti J, Rautio J (2010) Brain uptake of ketoprofen–lysine prodrug in rats. Int J Pharm 399:121–128CrossRefPubMedGoogle Scholar
  33. 33.
    Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327–338CrossRefPubMedGoogle Scholar
  34. 34.
    Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, Shimohama S (2000) The 4F2hc/LAT1 complex transports l-DOPA across the blood–brain barrier. Brain Res 879:115–121CrossRefPubMedGoogle Scholar
  35. 35.
    Wang Q, Morris ME (2007) Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos 35:201–208CrossRefPubMedGoogle Scholar
  36. 36.
    Gynther M, Laine K, Ropponen J, Leppanen J, Mannila A, Nevalainen T, Savolainen J, Jarvinen T, Rautio J (2008) Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem 51:932–936CrossRefPubMedGoogle Scholar
  37. 37.
    Ylikangas H, Malmioja K, Peura L, Gynther M, Nwachukwu EO, Leppanen J, Laine K, Rautio J, Lahtela-Kakkonen M, Huttunen KM, Poso A (2014) Quantitative insight into the design of compounds recognized by the l-type amino acid transporter 1 (LAT1). ChemMedChem 9:2699–2707CrossRefPubMedGoogle Scholar
  38. 38.
    Shennan, DB, Thomson, J, Gow, IF, Travers, MT, Barber, MC (2004) l-leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and molecular identity of the transporter. Biochim Biophys Acta 1664:206–216CrossRefPubMedGoogle Scholar
  39. 39.
    Imai T (2006) Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21:173–185CrossRefPubMedGoogle Scholar
  40. 40.
    Braun D, Kinne A, Brauer AU, Sapin R, Klein MO, Kohrle J, Wirth EK, Schweizer U (2011) Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells. Glia 59:463–471CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.School of Pharmacy, Faculty of Health SciencesUniversity of Eastern FinlandKuopioFinland

Personalised recommendations